logo
Stitch Fix (NASDAQ:SFIX) Delivers Impressive Q1, Full-Year Sales Guidance is Optimistic

Stitch Fix (NASDAQ:SFIX) Delivers Impressive Q1, Full-Year Sales Guidance is Optimistic

Yahooa day ago

Personalized clothing company Stitch Fix (NASDAQ:SFIX) reported Q1 CY2025 results beating Wall Street's revenue expectations , but sales were flat year on year at $325 million. On top of that, next quarter's revenue guidance ($300.5 million at the midpoint) was surprisingly good and 4.3% above what analysts were expecting. Its GAAP loss of $0.06 per share was 45% above analysts' consensus estimates.
Is now the time to buy Stitch Fix? Find out in our full research report.
Revenue: $325 million vs analyst estimates of $314.6 million (flat year on year, 3.3% beat)
EPS (GAAP): -$0.06 vs analyst estimates of -$0.11 (45% beat)
Adjusted EBITDA: $11.01 million vs analyst estimates of $9 million (3.4% margin, 22.4% beat)
Revenue Guidance for Q2 CY2025 is $300.5 million at the midpoint, above analyst estimates of $288 million
EBITDA guidance for the full year is $45 million at the midpoint, above analyst estimates of $43.93 million
Operating Margin: -3%, up from -7.7% in the same quarter last year
Free Cash Flow Margin: 4.9%, similar to the same quarter last year
Active Clients: 2.35 million, down 280,000 year on year
Market Capitalization: $609.2 million
'Stitch Fix delivered strong third quarter results, marked by our overall return to year-over-year revenue growth,' said Matt Baer, CEO, Stitch Fix.
One of the original subscription box companies, Stitch Fix (NASDAQ:SFIX) is an online personal styling and fashion service that curates personalized clothing selections for customers.
Reviewing a company's long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Stitch Fix struggled to consistently generate demand over the last five years as its sales dropped at a 5.6% annual rate. This wasn't a great result and is a sign of poor business quality.
We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new product or trend. Stitch Fix's recent performance shows its demand remained suppressed as its revenue has declined by 13.6% annually over the last two years.
We can better understand the company's revenue dynamics by analyzing its number of active clients, which reached 2.35 million in the latest quarter. Over the last two years, Stitch Fix's active clients averaged 16.7% year-on-year declines. Because this number is lower than its revenue growth during the same period, we can see the company's monetization has risen.
This quarter, Stitch Fix's $325 million of revenue was flat year on year but beat Wall Street's estimates by 3.3%. Company management is currently guiding for a 6% year-on-year decline in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to remain flat over the next 12 months. While this projection suggests its newer products and services will spur better top-line performance, it is still below the sector average.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Stitch Fix's operating margin has been trending up over the last 12 months, but it still averaged negative 6.9% over the last two years. This is due to its large expense base and inefficient cost structure.
In Q1, Stitch Fix generated a negative 3% operating margin. The company's consistent lack of profits raise a flag.
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable.
Stitch Fix's earnings losses deepened over the last five years as its EPS dropped 24.5% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. Consumer Discretionary companies are particularly exposed to this, and if the tide turns unexpectedly, Stitch Fix's low margin of safety could leave its stock price susceptible to large downswings.
In Q1, Stitch Fix reported EPS at negative $0.06, up from negative $0.18 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Stitch Fix's full-year EPS of negative $0.46 will reach break even.
We were impressed by how significantly Stitch Fix blew past analysts' revenue, EPS, and EBITDA expectations this quarter. We were also glad its full-year EBITDA guidance outperformed Wall Street's estimates. Zooming out, we think this was a solid print. The market seemed to be hoping for more, and the stock traded down 4.6% to $4.59 immediately after reporting.
Big picture, is Stitch Fix a buy here and now? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstroNova Announces Segment Leadership Promotions to Drive Execution of Growth Strategy
AstroNova Announces Segment Leadership Promotions to Drive Execution of Growth Strategy

Yahoo

time13 minutes ago

  • Yahoo

AstroNova Announces Segment Leadership Promotions to Drive Execution of Growth Strategy

WEST WARWICK, R.I., June 12, 2025--(BUSINESS WIRE)--AstroNova, Inc. (Nasdaq: ALOT), a leading innovator in data visualization technology, today announced the promotion of Jorik Ittmann to Senior Vice President of Product Identification. Jorik joins Tom Carll, who was promoted to Senior Vice President of Aerospace, at the end of the first quarter as the leaders of AstroNova's two segments. Both Jorik and Tom will continue to report directly to President and Chief Executive Officer Gregory Woods. Mr. Ittmann and Mr. Carll will be responsible for driving the sales, marketing and operational execution of the Product Identification and Aerospace segments, respectively. Both executives are responsible for and will be compensated on the financial performance of their segments, reinforcing AstroNova's commitment to driving accountability and long-term growth across the organization. Jorik Ittmann, who joined AstroNova in September 2024 as Vice President of Commercial Operations for the Product Identification segment, brings more than 20 years of global sales and business development experience across the healthcare and printing technology industries. Prior to AstroNova, he held senior roles at Zebra Technologies and Health Link Solutions, where he led revenue growth, expanded international markets, and strengthened sales teams. Tom Carll has been a vital member of AstroNova's leadership team since joining the company in 1989. Over the course of his career, he has held a variety of senior positions, including Sales Engineer, National Sales Manager for the Test & Measurement group, and leadership roles within the Aerospace segment since its inception in 2004. "Jorik and Tom have played critical roles in advancing our Product Identification and Aerospace businesses in the last six months and this organizational structure reflects the confidence we have in their continued executional focus," said Greg Woods, President and CEO of AstroNova. "Their expanded responsibilities and new simplified reporting structure will better align execution, support segment growth, and position us to unlock value for our customers and shareholders." About AstroNova AstroNova (Nasdaq: ALOT), a global leader in data visualization technologies since 1969, designs, manufactures, distributes and services a broad range of products that acquire, store, analyze, and present data in multiple formats. Its strategy is to drive profitable growth through innovative new technologies, building its installed base to expand recurring revenue while strategically sourcing its replacement products. The Product Identification segment provides a wide array of digital, end-to-end product marking and identification solutions, including hardware, software, and supplies for OEMs, commercial printers, and brand owners. The Aerospace segment provides products designed for airborne printing solutions, avionics, and data acquisition. Aerospace products include flight deck printing solutions, networking hardware, and specialized aerospace-grade supplies. Data acquisition systems are used in research and development, flight testing, missile and rocket telemetry, production monitoring, power, and maintenance applications. For more information please visit: Important Additional Information In connection with its 2025 Annual Meeting of Shareholders, AstroNova has filed a definitive proxy statement with the SEC and caused it to be mailed, together with an annual report and proxy card, to each of our shareholders. The proxy statement and a copy of the other materials that we file with the SEC from time to time, including our Annual Report on Form 10-K, as amended, for the fiscal year ended January 31, 2025, may be obtained free of charge via the Internet at and through the Investor Relations page of our corporate website, In addition, investors and security holders may obtain free copies of the proxy statement, the annual report and other proxy materials by directing a written request to ALOTproxy@ The proxy statement and other relevant materials we have made or will make available contain important information about the director nominees and the other matters to be voted upon by shareholders at the 2025 Annual Meeting of Shareholders. AstroNova urges shareholders to read the proxy statement, and any other relevant materials we make available, before making any decision with respect to the matters to be voted upon at the 2025 Annual Meeting of Shareholders, including the election of directors. View source version on Contacts Investor/Media Contact:Deborah Pawlowski, IRC, Alliance AdvisorsEmail: dpawlowski@ Phone: 716.843.3908

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Business Wire

time14 minutes ago

  • Business Wire

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under 'Events' in the Investors section of the Company's website. Participants may register to join the live call by following the link here to receive the dial-in numbers and unique PIN to access the call. Those who plan on participating are advised to join 15 minutes prior to the start time. A webcast replay of the call will be available on Vistagen's website about 24 hours after the end of the live conference call and will be accessible for at least 30 days. About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists to peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen's neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at

GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions
GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions

Business Wire

time18 minutes ago

  • Business Wire

GE HealthCare advances precision care with MIM Encore™ to deliver next-generation digital imaging and workflow solutions

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare's proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagnostic confidence, streamline workflows, and support the future of personalized medicine. 'In today's rapidly evolving healthcare landscape, operational efficiency and seamless collaboration are not just goals — they're the cornerstone to success. That's why we aim to provide tools that can help enhance providers' confidence in decision making and support patients in receiving personalized care,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We are committed to delivering technology that unifies data across systems and organizations, breaking down workflow barriers to help drive better clinical outcomes and elevate the standard of patient care.' New capabilities now available to GE HealthCare, MIM Software customers Now featuring dedicated post-processing tools for GE HealthCare systems, MIM Encore helps deliver excellent image quality with minimal effort, streamlining everyday nuclear medicine and cardiology workflows. Users can expect high image quality with minimal effort, along with automated read preparation, structured reporting, and flexible interpretation tools for PET/CT, SPECT/CT, and multi-modality fusion — all in a single platform. MIM Encore empowers clinicians and researchers to help deliver fast, accurate diagnoses, and onboard users quickly, for efficiencies and consistencies in work and communication between clinicians. 'Customers are telling us that this pairing is exactly what users have been looking for. The combined solution enables streamlined, accurate reading of images, supports quantitative analysis out of the box, and helps eliminate manual entries,' says Andrew Nelson, CEO, MIM Software, a GE HealthCare Company. 'As we continue to evolve our vertically integrated products based on user input, we remain focused on creating a user-friendly, vendor-neutral, future ready experience designed to scale with advanced molecular imaging needs.' With easy adoption across departments and roles — as well as few manual steps — MIM Encore adds resolution recovery and image-enhancing tools tailored for GE HealthCare scanners, streamlining workflows while helping elevate diagnostic confidence across care areas. Oncology: MIM Software's tools, now paired with GE HealthCare systems, simplify SPECT image processing with reconstruction and configurable enhancements, including resolution recovery, attenuation and scatter correction, advanced filtering, and motion correction. As a result, clinicians can view dynamic and static scans, share images easily, and access advanced quantitation tools — helping deliver clear insights with less manual effort. Cardiology: GE HealthCare's cardiac imaging is now even stronger with MIM technology's advanced PET and SPECT tools, enabling fast, high-quality reconstructions and quantitative analysis. Features like motion correction, automated quality checks, and intuitive displays help deliver accurate and efficient cardiac care. With support for key radiotracers and advanced algorithms like Evolution for Cardiac — developed at Johns Hopkins and University of North Carolina — MIM Encore is designed to deliver high-quality images at reduced acquisition times or doses i. Neurology: As a leader in neurodegenerative imaging, GE HealthCare with MIM technology now offers reconstruction workflows with 3D rendering and advanced corrections. As a result, clinicians benefit from consistent, high-quality images and easy-to-use tools for confident diagnosis, and assistance in treatment planning and evaluation. Also new, GE HealthCare's Effortless Workflow seamlessly integrates with MIM Encore, enabling clinicians to manage rising caseloads with intuitive interfaces, customizable displays, and automation that can help bridge experience gaps and reduces burnout. GE HealthCare acquired MIM Software in 2024, bringing together two industry leaders with expertise in multi-modality imaging, quantitation, workflow automation and molecular imaging. For more information on GE HealthCare's molecular imaging portfolio – including MIM Encore – please visit and SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store